Entities / Company
Eli Lilly and Company.
American pharmaceutical company
- Reports this week
- 31
- Active events
- 28
- Connections
- 875
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Eli Lilly and Company acquired Point and established a supply agreement with EUZ.Some support1 report
-
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Well supported17 reports1 development inside
-
Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.Some support1 report
-
Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Well supported11 reports3 developments inside
-
Eli Lilly's expansion in LEAP is driving local economic activity, benefiting from its proximity to Indianapolis.Some support1 report1 development inside
-
Eli Lilly and Company announced a $4.5 billion investment in its facilities located in Indiana.Some support1 report
-
Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.Some support1 report
-
Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.Some support2 reports
-
Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.Some support1 report
-
Eli Lilly developed an investigational treatment in South Africa, with the National Prosecuting Authority supporting the handling of medicine cases.Some support1 report
-
Jim Cramer's trust bought Kimberly-Clark shares and exited Corning, while discussing the strong performance of companies like Eli Lilly on CNBC.Some support1 report
-
Eli Lilly and Company collaborated with Adlai Nortye Ltd. for a clinical trial supply agreement.Some support1 report
-
Eli Lilly's drug is being illegally sold in South Africa.Some support2 reports
-
FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Some support1 report
-
County judge handles school board vacancy, with Eli Lilly serving as superintendent.Some support1 report
-
Eli Lilly and Company and Lockheed Martin are mentioned as active market players.Some support1 report
-
Foghorn's FHD-909 trial advances with Eli Lilly and Company.Some support3 reports
-
Semiconductor stocks are declining, prompting portfolio adjustments, while Eli Lilly and Honeywell are also noted in market activity.Some support1 report
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported4 reports2 developments inside
-
Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Some support1 report
-
Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.Some support1 report
-
Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.Well supported3 reports
-
FDA granted Fast Track designation while PTC Therapeutics and Eli Lilly acquired assets from Sangamo Therapeutics.Some support1 report
-
Bank of America and Citigroup issued buy ratings and raised price targets on July 18, 2026.Some support2 reports
-
Eli Lilly and Company met with the Lebanon city council and announced plans for construction and local funding.Some support1 report
-
A fund has changed its holdings, replacing JPMorgan Chase with Eli Lilly and Company.Some support1 report
-
The new event details specific stock holdings and composition facts for major ETFs like VOO and VGT.Some support1 report
Earlier this month
-
Eli Lilly personnel previously worked at McDaniel College and University of Maryland, and now serves as McDaniel College's president.Some support1 report
-
Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.Some support1 report
-
AbbVie and Eli Lilly are competing in the pharmaceutical market.Well supported7 reports
-
Hanmi Pharmaceutical won approval for its homegrown GLP-1 obesity drug, while Eli Lilly expands its market presence.Some support1 report
-
Market activity shows convenience store consolidation and rail freight activity, alongside company listings on Nasdaq.Some support1 report
-
Eli Lilly and Company issued a press release from Indianapolis and presented data at a conference in Las Vegas.Some support2 reports
-
Michael Yee provided stock views on Novo Nordisk and Eli Lilly on October 8, 2026.Some support1 report
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Well supported3 reports3 developments inside
-
Morgan Stanley, Kidder, and Capital Research Global Investors increased their holdings or boosted positions in Eli Lilly shares.Some support3 reports2 developments inside
-
YHB Investment Advisors Inc. grew its holdings in Eli Lilly and Company stock.Some support1 report
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported11 reports5 developments inside
-
Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.Some support1 report1 development inside
-
Studies involving Eli Lilly and Novo Nordisk report reductions in biological age using aging-clock methods.Some support2 reports
-
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Well supported29 reports6 developments inside
-
Novo announced a strategic partnership with Anthropic, Mike Doustdar was installed as CEO, and Eli Lilly gained market share in obesity care.Some support2 reports
-
Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.Some support1 report
-
Eli Lilly and AstraZeneca are involved in drug development and market competition, with the FDA issuing approvals and legal actions involving both companies.Some support1 report
-
Acquisition of ImClone Systems provided an oncology franchise.Some support1 report
-
Eli Lilly and Novo Nordisk developed GLP-1 weight-loss drugs, coinciding with operational status changes at SSA offices in New York.Some support1 report
-
Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.Well supported17 reports1 development inside
-
MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.Some support2 reports
-
FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.Well supported3 reports2 developments inside
-
Market trends on August 11, 2026, show the Indian market's influence on specialized healthcare stocks, global tech giants, and global risk appetite, factoring in the Middle East.Some support1 report1 development inside
-
Conflict in the Middle East is driving up energy prices, impacting costs for companies like Nvidia and Eli Lilly.Some support3 reports
-
GLP-1 drugs have been reported to reduce biological age.Some support2 reports
-
Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.Some support2 reports2 developments inside
-
IBM and Eli Lilly and Company are listed as active companies in the market.Some support3 reports
-
Eli Lilly and Company leveraged Ginkgo Bioworks' data points to accelerate drug discovery using AI.Some support1 report
-
ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Some support1 report
-
The FDA approved Olumiant for pediatric indications on September 1, 2026.Some support1 report
-
Eli Lilly and Company filed a disclosure with the Securities and Exchange Commission on June 15, 2026.Well supported22 reports1 development inside
-
Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Eli Lilly and Company
Events traced to Eli Lilly and Company, step by step, newest first- Hobart grant could boost skilled labor supply for Eli LillyHobart grant may improve skilled labor availability for Eli LillyPossible
- New Gilead HIV regimen may intensify competition for Eli LillyNew Gilead HIV regimen may intensify competition for Eli Lilly.Possible
- Moderna's vaccine combination increases competition for Eli LillyIncreased competitive pressure in advanced drug development for Eli LillyPossible
- J&J's strong drug performance may increase competitive pressure on Eli LillyJ&J's strong drug sales could intensify competition for Eli Lilly in key markets.Possible
- New Huntsville parkway may ease logistics for Eli LillyImproved Huntsville parkway may lower operational costs for Eli LillyPossible
- Eli Lilly may face market pressure from GLP-1 drug competitionIntense GLP-1 competition may pressure Eli Lilly and Company's market positionLikely
See all 27 explainers
- Protein degrader boom intensifies rivalry for Eli LillyIntense market rivalry could challenge Eli Lilly and Company in high-growth therapeutic areasPossible
- MindWalk's talent boost increases competitive pressure on Eli LillyMindWalk's talent boost increases competitive pressure on Eli LillyPossible
- How could the NICE appraisal of a testosterone cream affect Eli Lilly and Company?NICE appraisal may determine market access for testosterone creamPossible
- Regulatory streamlining may increase competition for Eli LillyIncreased biosimilar competition may put pressure on Eli Lilly's market pricingPossible
- Gas tax suspensions may lower operational costs for Eli LillyLower fuel prices may reduce operational costs for Eli Lilly and CompanyPossible
- New AhR agonist development may increase competition for Eli LillyNew AhR agonist development may increase competition for Eli LillyPossible
- New Korean obesity drug may intensify price competition for Eli LillyNew Korean obesity drug may intensify price competition for Eli LillyPossible
- Improved local infrastructure may boost Eli Lilly and Company's operational reliabilityImproved local infrastructure may boost Eli Lilly and Company's operational reliability.Possible
- J&J's strategic pivot could change pharma competition for Eli LillyJ&J's focus shift may alter competitive landscape for Eli LillyPossible
- Economic stress may curb consumer demand for Eli Lilly's productsReduced consumer purchasing power may curb demand for Eli Lilly's productsPossible
- Increased regulatory enforcement against price gouging may raise compliance risks for Eli Lilly and CompanyIncreased regulatory enforcement against price gouging may raise compliance risks for Eli Lilly and Company.Possible
- New pill for Parkinson's could challenge Eli Lilly's neurological portfolioNew once-daily Parkinson's drug may increase competition for Eli LillyPossible
- Rising Medicare costs may shift drug spending burden to Eli Lilly's customersEli Lilly and Company may see shifts in drug revenue due to Medicare cost changesPossible
- J&J's strong pharma results may intensify competition for Eli LillyJ&J's strong pharma results may intensify competition for Eli LillyPossible
- Medicare price negotiation could challenge Eli Lilly's drug pricingEli Lilly and Company could face pressure on drug pricing and revenue streams.Possible
- JNJ and AbbVie co-commercialization intensifies competition for Eli LillyIncreased competition from JNJ and AbbVie may challenge Eli Lilly's market share.Possible
- Increased competition for investment capital may intensify market rivalry for Eli Lilly and CompanyIncreased competition for investment capital may intensify market rivalry for Eli Lilly and Company.Possible
- Medicare payment cut may change drug pricing for Eli LillyEli Lilly and Company may face changes in revenue due to proposed Medicare drug payment cutsPossible
- Bausch + Lomb's potential oral AMD drug may increase competition for Eli LillyBausch + Lomb's potential oral AMD drug may increase competition for Eli LillyPossible
- Eli Lilly's philanthropic investment reinforces Indiana youth programsEli Lilly and Company's philanthropic investment in Indiana continues through youth fundingLikely
- Medicare cuts may alter pricing and demand for Eli Lilly and CompanyMedicare cuts could potentially reduce revenue and alter pricing for Eli Lilly and CompanyPossible
Explainers that pass through Eli Lilly and Company
Eli Lilly and Company is a step on the way to someone elseAround Eli Lilly and Company this week
News at the entities that move Eli Lilly and Company most-
FDA StructuralHemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.Moves Eli Lilly and Company
-
Indiana StructuralA city in Indiana has offered a grant to support local workforce readiness initiatives.Moves Eli Lilly and Company
-
Novo Nordisk OperationalPersonnel changes at Novo Nordisk and Lundbeck, including Mike Doustdar succeeding Lars Fruergaard Jørgensen and proposals for Lundbeck's board.Moves Eli Lilly and Company
-
Pfizer OperationalAbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Moves Eli Lilly and Company
-
Federal Trade Commission StructuralThe Federal Trade Commission launched an investigation into major brewers, including Asahi Breweries and Anheuser-Busch.Moves Eli Lilly and Company
-
Medicare StructuralHRSA classifies rural hospitals in Arkansas, showing high risk of closure in Arkansas, Connecticut, and Rhode Island due to Medicare cost data.Moves Eli Lilly and Company
Connections
The 40 strongest of 875, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Eli Lilly's drug development, approval, and market activities, determining product viability and market access.
-
Indiana Structural
Eli Lilly and Company is structurally integrated into Indiana, relying on the state for its operational base while making massive investments and partnering on public health programs.
-
David Ricks Structural
David Ricks serves as the Chief Executive Officer of Eli Lilly and Company.
-
Viking Therapeutics Operational
Viking Therapeutics and Eli Lilly are direct competitors in the high-stakes market for GLP-1/GIP agonist drugs targeting obesity and weight management.
-
Novo Nordisk Operational
The two pharmaceutical companies are engaged in intense, high-stakes competition for global market leadership in the obesity and diabetes drug market.
-
Pfizer Operational
Pfizer and Eli Lilly are direct competitors vying for market share in high-growth pharmaceutical sectors, particularly GLP-1 weight loss and oncology.
-
Norges Bank Transactional
Norges Bank has repeatedly purchased new stakes and increased its holdings in Eli Lilly and Company.
-
Verve Transactional
Eli Lilly and Company planned and initiated the acquisition of Verve Therapeutics for up to $1.3 billion.
Show all 40 connections
-
Nicholas Noyes Structural
Nicholas Noyes served as a vice president and director of Eli Lilly and Company.
-
Generation Park Structural
Eli Lilly is establishing a $6.5 billion manufacturing facility at Generation Park.
-
AbbVie Operational
AbbVie and Eli Lilly are direct competitors in the pharmaceutical market, vying for market share and therapeutic dominance.
-
Houston Structural
Eli Lilly and Company is establishing and operating a major $6.5 billion manufacturing facility in Houston.
-
Elanco Structural
Elanco was historically a division and subsidiary of Eli Lilly and Company.
-
Johnson & Johnson Operational
The two pharmaceutical giants are engaged in direct, high-stakes market competition across various therapeutic and growth segments.
-
Novo Nordisk Operational
The two companies are direct, high-stakes competitors in the global weight loss and diabetes drug markets, evidenced by market rivalry and active litigation.
-
Goochland County Shared context
Eli Lilly and Company has established a manufacturing facility within Goochland County.
-
ImClone Systems Structural
Eli Lilly acquired ImClone Systems, integrating its oncology franchise.
-
CVS Health Operational
CVS and Eli Lilly engage in a dynamic operational relationship characterized by both market competition (formulary decisions) and strategic collaboration on patient access and distribution.
-
AstraZeneca Operational
Eli Lilly and AstraZeneca are active competitors in the pharmaceutical market, vying for market share in oncology and obesity.
-
Federal Trade Commission Structural
The Federal Trade Commission is formally regulating Eli Lilly, including mandating divestment and investigating market practices.
-
Medicare Structural
Medicare acts as the primary payer and regulatory gatekeeper, determining coverage and pricing for Eli Lilly's pharmaceutical products.
-
Morgan Stanley Operational
Morgan Stanley provides investment research and adjusts its holdings, directly influencing the market valuation of Eli Lilly.
-
Max Denning Structural
Max Denning serves as an associate vice president at Eli Lilly and Company.
-
Amgen Operational
Both companies are direct competitors in advanced drug markets, specializing in GLP-1 agonists, obesity treatments, and Lp(a) reduction.
-
Bank of America Operational
Bank of America actively uses its analyst coverage and rating changes to influence the market perception and stock performance of Eli Lilly.
-
Huntsville Structural
Eli Lilly is establishing a major manufacturing project and making a $6 billion investment in Huntsville.
-
Novartis Operational
The relationship is intense market competition, rooted in the historical divestiture of Novartis' Animal Health division to Lilly.
-
Health Resources and Services Administration Structural
Eli Lilly and Company is subject to compliance and oversight requirements and reporting mandates from the Health Resources and Services Administration.
-
European Medicines Agency Structural
The EMA's regulatory recommendations and approvals directly determine Eli Lilly's market access and financial performance in Europe.
-
Francisco Ramírez-Valle Structural
Francisco Ramírez-Valle serves as a Senior Vice President in the research division of Eli Lilly and Company.
-
Jim Cramer Operational
Jim Cramer actively provides market commentary, tracking, and bullish support for Eli Lilly and Company's stock and pipeline.
-
Alabama Structural
Eli Lilly is committing $6 billion to establish a major operational presence with new manufacturing plants in Alabama.
-
Nvidia Operational
Nvidia and Eli Lilly maintain an active partnership, leveraging Nvidia's AI infrastructure for joint drug discovery and co-innovation initiatives.
-
VOO Structural
Eli Lilly is a major component holding within the VOO ETF.
-
Wang Li Structural
Wang Li serves as the head of the drug development center in China for Eli Lilly and Company.
-
Donald Trump Operational
Trump utilizes political pressure, tariffs, and policy agreements to influence Eli Lilly's manufacturing, pricing, and investment strategies.
-
China Structural
Eli Lilly relies on China for market access, national reimbursement, and drug sourcing.
-
Merck KGaA Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Securities and Exchange Commission Structural
Eli Lilly and Company is structurally required to file institutional reports, such as Form 13F, with the SEC.
-
SEC Structural
Eli Lilly and Company is structurally required to file institutional holdings and stock transaction reports with the SEC.
History
Events by the month they beganOctober 2026
38 events- Eli Lilly and Company acquired Point and established a supply agreement with EUZ.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- Eli Lilly's expansion in LEAP is driving local economic activity, benefiting from its proximity to Indianapolis.
- Eli Lilly and Company announced a $4.5 billion investment in its facilities located in Indiana.
- Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.
- Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.
- Eli Lilly developed an investigational treatment in South Africa, with the National Prosecuting Authority supporting the handling of medicine cases.
- Jim Cramer's trust bought Kimberly-Clark shares and exited Corning, while discussing the strong performance of companies like Eli Lilly on CNBC.
- Eli Lilly and Company collaborated with Adlai Nortye Ltd. for a clinical trial supply agreement.
- Eli Lilly's drug is being illegally sold in South Africa.
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.
- County judge handles school board vacancy, with Eli Lilly serving as superintendent.
- Eli Lilly and Company and Lockheed Martin are mentioned as active market players.
- Semiconductor stocks are declining, prompting portfolio adjustments, while Eli Lilly and Honeywell are also noted in market activity.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- FDA granted Fast Track designation while PTC Therapeutics and Eli Lilly acquired assets from Sangamo Therapeutics.
- Eli Lilly and Company met with the Lebanon city council and announced plans for construction and local funding.
- A fund has changed its holdings, replacing JPMorgan Chase with Eli Lilly and Company.
- The new event details specific stock holdings and composition facts for major ETFs like VOO and VGT.
- Eli Lilly personnel previously worked at McDaniel College and University of Maryland, and now serves as McDaniel College's president.
- Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.
- Hanmi Pharmaceutical won approval for its homegrown GLP-1 obesity drug, while Eli Lilly expands its market presence.
- Market activity shows convenience store consolidation and rail freight activity, alongside company listings on Nasdaq.
- Eli Lilly and Company issued a press release from Indianapolis and presented data at a conference in Las Vegas.
- Michael Yee provided stock views on Novo Nordisk and Eli Lilly on October 8, 2026.
- YHB Investment Advisors Inc. grew its holdings in Eli Lilly and Company stock.
- Studies involving Eli Lilly and Novo Nordisk report reductions in biological age using aging-clock methods.
- Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.
- Eli Lilly and AstraZeneca are involved in drug development and market competition, with the FDA issuing approvals and legal actions involving both companies.
- Acquisition of ImClone Systems provided an oncology franchise.
- Eli Lilly and Novo Nordisk developed GLP-1 weight-loss drugs, coinciding with operational status changes at SSA offices in New York.
- MarketBeat listed Johnson & Johnson, Medtronic plc, and Eli Lilly and Company as top healthcare stocks on October 7, 2026.
- Conflict in the Middle East is driving up energy prices, impacting costs for companies like Nvidia and Eli Lilly.
- GLP-1 drugs have been reported to reduce biological age.
- IBM and Eli Lilly and Company are listed as active companies in the market.
- Eli Lilly and Company leveraged Ginkgo Bioworks' data points to accelerate drug discovery using AI.
September 2026
6 events- Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.
- Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
- Novo announced a strategic partnership with Anthropic, Mike Doustdar was installed as CEO, and Eli Lilly gained market share in obesity care.
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.
- The FDA approved Olumiant for pediatric indications on September 1, 2026.
- Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.
August 2026
6 events- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.
- Foghorn's FHD-909 trial advances with Eli Lilly and Company.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Market trends on August 11, 2026, show the Indian market's influence on specialized healthcare stocks, global tech giants, and global risk appetite, factoring in the Middle East.
- Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.
Show 2 earlier months
July 2026
1 eventJune 2026
9 events- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- Morgan Stanley, Kidder, and Capital Research Global Investors increased their holdings or boosted positions in Eli Lilly shares.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- Eli Lilly and Company filed a disclosure with the Securities and Exchange Commission on June 15, 2026.